Fetal therapy in fetal thyrotoxicosis: A case report

Introduction: Fetal thyrotoxicosis, often caused by maternal Grave's disease, can have adverse effects on fetal outcomes, such as growth impairment or fetal hydrops. Therefore, intrauterine treatment is recommended. Objective: To describe the experience of intrauterine medical treatment of feta...

Full description

Saved in:
Bibliographic Details
Main Authors: Kasemsri Srisupundit, Supatra Sirichotiyakul, Fuanglada Tongprasert, Suchaya Luewan, Theera Tongsong
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40049093261&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/60674
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-60674
record_format dspace
spelling th-cmuir.6653943832-606742018-09-10T03:47:00Z Fetal therapy in fetal thyrotoxicosis: A case report Kasemsri Srisupundit Supatra Sirichotiyakul Fuanglada Tongprasert Suchaya Luewan Theera Tongsong Medicine Introduction: Fetal thyrotoxicosis, often caused by maternal Grave's disease, can have adverse effects on fetal outcomes, such as growth impairment or fetal hydrops. Therefore, intrauterine treatment is recommended. Objective: To describe the experience of intrauterine medical treatment of fetal thyrotoxicosis. Case: A 19-year-old woman with a history of Grave's disease in a euthyroid clinical status after subtotal thyroidectomy became pregnant 2 months after thyroidectomy. At gestational age 28 weeks, persistent fetal tachycardia was identified and the diagnosis of fetal thyrotoxicosis was established by fetal thyroid function test on umbilical cord blood obtained by cordocentesis. Intrauterine treatment for hyperthyroidism was initiated with antithyroid drugs (150 mg/day of propylthiouracil) via maternal oral administration. Fetal heart rate, size of fetal thyroid gland and umbilical cord blood sampling for thyroid function test were monitored. Fetal heart rate became normal and fetal thyroid function tested on fetal cord blood at 1 month after antithyroid fetal therapy was also normal. Fetal thyrotoxicosis improved but the mother had some degree of hypothyroidism from fetal therapy and needed thyroid hormone replacement. The remaining course of gestation was uneventful. The patient had spontaneous labor and delivery at 38 weeks of gestation resulting in normal female baby, 2,900 g, and had no clinical of neonatal thyrotoxicosis. Maternal thyroid medications were stopped immediately after birth. Conclusion: Intrauterine treatment of fetal thyrotoxicosis with medication via the maternal circulation can possibly improve fetal outcome. Copyright © 2007 S. Karger AG. 2018-09-10T03:47:00Z 2018-09-10T03:47:00Z 2008-02-01 Journal 10153837 2-s2.0-40049093261 10.1159/000111589 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40049093261&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/60674
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Kasemsri Srisupundit
Supatra Sirichotiyakul
Fuanglada Tongprasert
Suchaya Luewan
Theera Tongsong
Fetal therapy in fetal thyrotoxicosis: A case report
description Introduction: Fetal thyrotoxicosis, often caused by maternal Grave's disease, can have adverse effects on fetal outcomes, such as growth impairment or fetal hydrops. Therefore, intrauterine treatment is recommended. Objective: To describe the experience of intrauterine medical treatment of fetal thyrotoxicosis. Case: A 19-year-old woman with a history of Grave's disease in a euthyroid clinical status after subtotal thyroidectomy became pregnant 2 months after thyroidectomy. At gestational age 28 weeks, persistent fetal tachycardia was identified and the diagnosis of fetal thyrotoxicosis was established by fetal thyroid function test on umbilical cord blood obtained by cordocentesis. Intrauterine treatment for hyperthyroidism was initiated with antithyroid drugs (150 mg/day of propylthiouracil) via maternal oral administration. Fetal heart rate, size of fetal thyroid gland and umbilical cord blood sampling for thyroid function test were monitored. Fetal heart rate became normal and fetal thyroid function tested on fetal cord blood at 1 month after antithyroid fetal therapy was also normal. Fetal thyrotoxicosis improved but the mother had some degree of hypothyroidism from fetal therapy and needed thyroid hormone replacement. The remaining course of gestation was uneventful. The patient had spontaneous labor and delivery at 38 weeks of gestation resulting in normal female baby, 2,900 g, and had no clinical of neonatal thyrotoxicosis. Maternal thyroid medications were stopped immediately after birth. Conclusion: Intrauterine treatment of fetal thyrotoxicosis with medication via the maternal circulation can possibly improve fetal outcome. Copyright © 2007 S. Karger AG.
format Journal
author Kasemsri Srisupundit
Supatra Sirichotiyakul
Fuanglada Tongprasert
Suchaya Luewan
Theera Tongsong
author_facet Kasemsri Srisupundit
Supatra Sirichotiyakul
Fuanglada Tongprasert
Suchaya Luewan
Theera Tongsong
author_sort Kasemsri Srisupundit
title Fetal therapy in fetal thyrotoxicosis: A case report
title_short Fetal therapy in fetal thyrotoxicosis: A case report
title_full Fetal therapy in fetal thyrotoxicosis: A case report
title_fullStr Fetal therapy in fetal thyrotoxicosis: A case report
title_full_unstemmed Fetal therapy in fetal thyrotoxicosis: A case report
title_sort fetal therapy in fetal thyrotoxicosis: a case report
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40049093261&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/60674
_version_ 1681425479511310336